AT-16: PHASE II STUDY OF TIVOZANIB, AN ORAL VEGFR INHIBITOR, IN PATIENTS WITH RECURRENT GLIOBLASTOMA
AT-16：口服VEGFR抑制剂替沃扎尼治疗复发性胶质母细胞瘤患者的II期研究
期刊:Journal of Clinical and Diagnostic Research
影响因子:0.2
doi:10.7860/JCDR/2016/20773.8269
Kolla, Gautham; Acharya, Vishak; Balanthimogru, Prashantha; Mani, Arun; Ruman, Shehzad; Ovando, Dennerd; Iregui, Adriana Carrillo; Christin, Nicole M; Fecteau, Kellie; Giori, Luca; Esteller-Vico, Alex; Eiler, Hugo; Jabr, Ra’ed; El Atrouni, Wissam; Male, Heather; Hammoud, Kassem; Chandra, Vyshak; Ou, Yangming; Evans, John; Kalpathy-Cramer, Jayashree; Dietrich, Jorg; Chi, Andrew; Wen, Patrick; Rosen, Bruce; Batchelor, Tracy; Gerstner, Elizabeth
